Tipifarnib and Gemcitabine Hydrochloride in Treating Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of tipifarnib when given
together with gemcitabine hydrochloride and to see how well they work in treating women with
breast cancer that has spread to other parts of the body. Tipifarnib is a drug that binds to
specific proteins on the tumor cells and then kills these cells. Gemcitabine hydrochloride is
a chemotherapy drug that may kill tumor cells by preventing cells from dividing. Giving
tipifarnib together with gemcitabine hydrochloride may kill more tumor cells.